Adicet Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACET Nasdaq 2836 www.adicetbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adicet Bio, Inc.

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Jan 8th, 2025 9:10 pm
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Dec 31st, 2024 9:48 pm
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Dec 19th, 2024 12:00 pm
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - Dec 18th, 2024 12:00 pm
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Nov 18th, 2024 9:00 pm
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - Nov 18th, 2024 12:00 pm
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans? - Nov 18th, 2024 11:33 am
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 - Nov 16th, 2024 2:00 pm
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates - Nov 6th, 2024 9:00 pm
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 - Nov 5th, 2024 12:00 pm
Adicet Bio to Participate in Upcoming Investor Conferences - Nov 1st, 2024 11:00 am
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Oct 31st, 2024 9:31 pm
Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials - Oct 17th, 2024 11:27 am
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome - Oct 16th, 2024 11:00 am
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference - Sep 30th, 2024 8:30 pm
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases - Sep 30th, 2024 11:00 am
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue - Sep 19th, 2024 11:00 am
Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Aug 27th, 2024 8:00 pm
Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors - Aug 19th, 2024 11:00 am
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates - Aug 13th, 2024 11:00 am